Lilly Migraine Treatment Moves Forward

Posted: Updated:
Lilly plans to present trial results at scientific meetings and publications over the next year. Lilly plans to present trial results at scientific meetings and publications over the next year.
INDIANAPOLIS -

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) says its second Phase 3 study of an oral migraine treatment has yielded positive results. Lilly says as a result of the positive outcome for lasmiditan, the company plans to submit a New Drug Application with the U.S. Food and Drug Administration in the second half of 2018.

Lilly says the treatment met its primary endpoint in the SPARTAN study, which showed that a greater percentage of patients treated with lasmiditan were migraine pain-free compared to placebo after two hours of taking the first dose. The drug also met is secondary endpoint, which showed that a "statistically significantly greater percentage" of patients were free of their most bothersome symptoms, such as nausea and sensitivity to sound or light.

"Lasmiditan represents the first significant innovation in the acute treatment of migraine in more than 20 years, and could provide a much-needed new treatment option for the 36 million Americans living with migraine," said Christi Shaw, president of Lilly Bio-Medicines. "We are thrilled with these topline lasmiditan results, which add to more than 25 years of Lilly's research and development of migraine therapies."

The company plans to present data from both studies at scientific meetings and submit results to peer-reviewed journals over the next year. The company has already begun another Phase 3 study, known as GLADIATOR, to evaluate the long-term safety of the drug for the acute treatment of migraine.

The treatment was originally discovered by Lilly in 2005 and later sold the rights to lasmiditan to Massachusetts-based CoLucid Pharmaceuticals Inc, which continued to develop the drug. Lilly recently-completed a $960 million acquisition of CoLucid, a deal which was profiled by Inside INdiana Business Reporter Kylie Veleta in our Life Sciences INdiana e-newsletter.

  • Perspectives

    • Disagreeing Isn't Inherently Disagreeable

      Most of us have an inherent distaste for conflict. And somewhere along the way, society has reached a conclusion that disagreement is a bad thing. When it comes to business advice and decisions, that conclusion can be deadly. I see two factors that have contributed to the current state of disagreement. One is the national political climate, which is the most polarized I can remember since my father was snarling about those damned hippies. The other is social media, which seems to...

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • KAR's Big Carmel Investment About Talent 'Fight'

      KAR Auction Services Inc. (NYSE: KAR) Chief Executive Officer Jim Hallett says a planned $80 million investment in a new Carmel headquarters will serve the company's existing needs and boost talent attraction. Some 900 employees are located at the company's current HQ, and KAR says the new space will house 400 new workers that will be added in the coming years. Hallett says "we're all in a fight for talent," especially in the technology space. He calls central Indiana...

    • INDOT Discusses Timeline For 'North Split' Overhaul

      One of the busiest interchanges in the state is going to be rebuilt. The Indiana Department of Transportation has announced the overhaul of the I-65/I-70 North Split in Indianapolis will include rehabilitation or widening of 32 bridges, adding new bridges and making room for future through-lane capacity on both interstates. The interchange handles some 170,000 cars per day. It was built 50 years ago and INDOT says its "useful life" is nearing the end.

    • GOP: Trump Set For Indiana Visit

      The Indiana Republican Party says President Donald Trump will make an appearance in Indiana next week. Specific details regarding the visit, including a location, have not yet been released. 

    • KAR Auction Services Plans $80M Carmel Expansion

      Carmel-based KAR Auction Services Inc. (NYSE: KAR) has announced a headquarters expansion that is expected to create 400 jobs by 2020. The company plans to invest $80 million into what it says will be a state-of-the-art campus to house 1,500 workers. During an announcement Tuesday at the Center for the Performing Arts, Chief Executive Officer Jim Hallett said...

    • Cook Creates 'Really Big Day in Bloomington'

      The president of Bloomington-based Cook Group Inc. says Tuesday's agreement to sell its Cook Pharmica LLC subsidiary to New Jersey-based Catalent Inc. (NYSE: CTLT) and the decision to acquire a former General Electric facility near the company's headquarters will have a positive impact on the city and state. Pete Yonkman says the nearly $1 billion dollar deal for Cook Pharmica has been six months in the making.